Biocon Biologics and Viatris receives European Commission approval for Biosimilar Bevacizumab

Abevmy 100 & 400 mg, a biosimilar Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

from India Infoline News Service https://ift.tt/3aFMXyP